A Study on the Immune Response and Safety of an RSV Vaccine When Given to Adults 50 Years of Age and Above Who Received Lung or Kidney Transplant and Are at an Increased Risk of Respiratory Syncytial Virus Lower Respiratory Tract Disease and Compared to Healthy Adults 50 Years of Age and Above

Condition:   Respiratory Syncytial Virus Infections Intervention:   Biological: RSVPreF3 OA Investigational Vaccine Sponsor:   GlaxoSmithKline Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials